CA2651019A1 — Uses of dpp iv inhibitors
Assigned to Boehringer Ingelheim International GmbH · Expires 2007-11-15 · 19y expired
What this patent protects
Disclosed is the use of selected DPP-IV inhibitors for treating physiological functional disorders and reducing the risk of at-risk patient groups developing such functional disorders. Also disclosed is the use of said DPP-IV inhibitors in combination with other agents such that …
USPTO Abstract
Disclosed is the use of selected DPP-IV inhibitors for treating physiological functional disorders and reducing the risk of at-risk patient groups developing such functional disorders. Also disclosed is the use of said DPP-IV inhibitors in combination with other agents such that improved treatment results can be obtained. Said uses can be employed for producing corresponding medicaments.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.